| HOME >> BIOLOGY >> TECHNOLOGY |
NEW BRUNSWICK, N.J., July 3 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) announced today that it has contracted with Polyplus-transfection (Illkirch, France) to supply Polyplus's "in vivo-jetPEI" for systemic delivery of Senesco's combination therapy of siRNA against Factor 5A and a plasmid of the Factor 5A gene.
Senesco has previously reported positive preclinical in vivo results using its combination siRNA and plasmid delivered with "in vivo-jetPEI" against subcutaneous multiple myeloma tumors in immunodeficient mice.
"This supply agreement will help Senesco move toward the necessary preclinical toxicology study and ultimately the planned clinical trial targeting multiple myeloma," commented Bruce Galton, Senesco's President and CEO. "Polyplus' PEI technology is already being used in clinical oncology trials by other companies and we look forward to working with them and using their technology to deliver our Factor 5A technology."
"We are proud that Senesco has chosen our delivery system targeting multiple myeloma and that we have an agreement to supply the company according to this agreement," said Joelle Bloch, CEO of Polyplus-transfection. "We are delighted that our 'in vivo-jetPEI' will be used as delivery vehicle for a combination of siRNA and plasmid DNA in this therapeutic approach."
About Polyplus-transfection
Polyplus-transfection is focused on developing innovative solutions for delivery of biomolecules. The company has been marketing its transfection reagents worldwide since 2001 and is reinvesting most of its revenues in research and development.
Transfection consists in introducing a gene or a small interfering RNA
into cells. This tec
'/>"/>
| SOURCE Senesco Technologies, Inc. Copyright©2008 PR Newswire. All rights reserved |